FibroGen, Inc. (FGEN)

Market Cap	35.27M
Revenue (ttm)	180.02M
Net Income (ttm)	-121.79M
Shares Out	100.77M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,292,952
Open	0.359
Previous Close	0.350
Day's Range	0.335 - 0.360
52-Week Range	0.180 - 2.930
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 486
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN
• Website: https://www.fibrogen.com

Financial Performance

In 2023, FibroGen's revenue was $147.75 million, an increase of 4.99% compared to the previous year's $140.73 million. Losses were -$284.23 million, -3.21% less than in 2022.